Puma Biotechnology, Inc. (NASDAQ:PBYI) Forecasted to Post FY2025 Earnings of $0.19 Per Share

Puma Biotechnology, Inc. (NASDAQ:PBYI) – Zacks Research cut their FY2025 EPS estimates for Puma Biotechnology in a research note issued to investors on Thursday, September 26th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings per share of $0.19 for the year, down from their prior forecast of $0.22. The consensus estimate for Puma Biotechnology’s current full-year earnings is $0.25 per share.

PBYI has been the subject of several other research reports. HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Puma Biotechnology in a research note on Friday, August 2nd. StockNews.com downgraded shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 13th.

Puma Biotechnology Trading Up 2.0 %

NASDAQ PBYI opened at $2.60 on Monday. The firm has a 50 day simple moving average of $2.91 and a 200-day simple moving average of $3.80. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.23 and a current ratio of 1.32. Puma Biotechnology has a one year low of $2.13 and a one year high of $7.73. The firm has a market cap of $125.42 million, a price-to-earnings ratio of 7.88 and a beta of 1.09.

Puma Biotechnology (NASDAQ:PBYI) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. Puma Biotechnology had a net margin of 4.01% and a return on equity of 18.36%. The business had revenue of $47.10 million during the quarter, compared to analysts’ expectations of $43.99 million. During the same period last year, the business earned $0.05 earnings per share.

Insider Buying and Selling

In related news, CEO Alan H. Auerbach sold 21,920 shares of Puma Biotechnology stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $3.70, for a total value of $81,104.00. Following the completion of the transaction, the chief executive officer now owns 7,063,515 shares in the company, valued at $26,135,005.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CEO Alan H. Auerbach sold 21,920 shares of the business’s stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $3.70, for a total transaction of $81,104.00. Following the completion of the sale, the chief executive officer now owns 7,063,515 shares in the company, valued at approximately $26,135,005.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michael Patrick Miller sold 23,358 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $3.49, for a total transaction of $81,519.42. Following the sale, the director now owns 47,000 shares of the company’s stock, valued at approximately $164,030. The disclosure for this sale can be found here. Insiders sold 52,032 shares of company stock worth $187,613 over the last 90 days. 23.70% of the stock is owned by insiders.

Institutional Trading of Puma Biotechnology

Institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC purchased a new stake in shares of Puma Biotechnology during the 1st quarter worth approximately $57,000. Victory Capital Management Inc. purchased a new stake in shares of Puma Biotechnology during the 2nd quarter worth approximately $54,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Puma Biotechnology during the 2nd quarter worth approximately $58,000. Lazard Asset Management LLC increased its holdings in shares of Puma Biotechnology by 5,129.0% in the 1st quarter. Lazard Asset Management LLC now owns 49,466 shares of the biopharmaceutical company’s stock valued at $262,000 after acquiring an additional 48,520 shares during the period. Finally, Rhumbline Advisers increased its holdings in shares of Puma Biotechnology by 2,309.9% in the 2nd quarter. Rhumbline Advisers now owns 50,270 shares of the biopharmaceutical company’s stock valued at $164,000 after acquiring an additional 48,184 shares during the period. Hedge funds and other institutional investors own 61.29% of the company’s stock.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.